Image

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Recruiting
4 - 6 years of age
Both
Phase 2

Powered by AI

Overview

  • Primary objective is to assess the safety of MG1111 until Day 42 using as 2nd vaccination
    • Secondary objective to assess the immunogenicity and safety of MG1111 using as 2nd vaccination

Description

  1. Safety
    • Incidence of fever (temperature ≥39.0℃) within 42 days after the IP administration
    • Incidence of fever (temperature ≥39.0℃) within 7 days after the IP administration
    • Solicited local/systemic AEs occurred within 7 days after the IP administration
    • Unsolicited adverse events that occurred within 42 days after the IP administration
    • Serious adverse events that occurred within 1 year after the IP administration
    • Vital signs and physical examinations 2. Efficacy (Immunogenicity)

-GMT(Geometric Mean Titer) and GMR(Geometric Mean Ratio(fold change))measured by the glycoprotein enzyme-linked immunosorbent assay (gpELISA) at before and 42 days after the IP administration

3. Exploratory assessment

  • GMV and GMR of VZV-CMI response measured by INF-r ELISPOT at before and 42 days after the IP administration
  • GMT and GMR of the antibody titer measured by gpELISA at before and after the IP administration for 3 years
  • Varicella-like rash and Varicella-zoster virus genotyping analysis occurred after IP administration for 3 years

Eligibility

Inclusion Criteria:

  • Healthy children between 4 and 6 years of age as of the date of written consent
  • Subjects who have a history of 1st Varicella vaccination at least 3 years ago from the administration of investigational product
  • Subjects or parent/legal representative willing to provide written informed consent and able to comply with the study requirements
  • Negative history of Varicella infection

Exclusion Criteria:

  • Subjects with a history of exposure to varicella through contact with a varicella patient at home, school, or childcare facility within 4 weeks before the administration of investigational drug
  • Subjects who have a history 2 times or more of varicella vaccine injections
  • Subjects who had an acute febrile (at least 38.0 ℃) episode at some time during the 72 hours before the administration of investigational product
  • Subjects who had any suspected allergy symptoms including systemic rash during the 72 hours before the administration of investigational product
  • Subjects with a history of Guillain-Barre syndrome.
  • Subjects with a severe chronic disease and considered ineligible for the study at Investigator's discretion
  • Subjects with a history of hypersensitivity to any ingredient such as gelatin, antibiotics (Neomycin, Kanamycin, Erythromycin)
  • Active tuberculosis patient
  • Subjects who had received other vaccinations within 4 weeks before the administration of investigational product
  • Subjects with immunodeficiency history
  • Subjects who had received salicylates (aspirin, bismuth, subsalicylates) within 4 weeks before the administration of investigational drug
  • Subjects who administered immune globulin, gamma globulin, or blood products such as whole blood within 44 weeks before the administration of investigational drug
  • Subjects who had received immunosuppressant or immune modifying drug within 12 weeks before the administration of investigational drug
  • A. Azathioprine, Cyclosporin, Interferon, G-CSF, Tacrolimus, Everolimus, Sirolimus, etc.
  • B. Subjects who administered high dose of corticosteroids (greater than 2 mg/kg/day in case of under 10kg subjects or ≥20mg/day in case of above 10kg subject of prednisone for 14 days) (However, inhaled, intranasal, topical corticosteroids administration in allowed)
  • Subjects who administered anti-viral drug within 4 weeks before the administration of investigational drug
  • Subjects who have participated in any other clinical trials within 24 weeks of the administration of the investigational product
  • Subjects with other clinically significant medical or psychological condition who are considered by the Investigator to be ineligible for the study

Study details

Varicella

NCT05422508

Green Cross Corporation

29 January 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.